Arrowhead Pharmaceuticals, Inc. (ARWR)
62.75
+2.01
(+3.31%)
USD |
NASDAQ |
Oct 09, 16:00
62.58
-0.17
(-0.27%)
After-Hours: 20:00
Arrowhead Pharmaceuticals Free Cash Flow : -75.11M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -75.11M |
| March 31, 2026 | -45.87M |
| December 31, 2025 | 327.01M |
| September 30, 2025 | 156.89M |
| June 30, 2025 | -17.62M |
| March 31, 2025 | 4.596M |
| December 31, 2024 | -576.61M |
| September 30, 2024 | -604.32M |
| June 30, 2024 | -531.98M |
| March 31, 2024 | -470.16M |
| December 31, 2023 | -402.70M |
| September 30, 2023 | -330.63M |
| June 30, 2023 | -342.84M |
| March 31, 2023 | -353.17M |
| December 31, 2022 | -236.21M |
| September 30, 2022 | -188.91M |
| June 30, 2022 | -119.85M |
| March 31, 2022 | -75.00M |
| December 31, 2021 | 123.72M |
| September 30, 2021 | 147.66M |
| June 30, 2021 | 167.24M |
| March 31, 2021 | 165.21M |
| December 31, 2020 | -122.69M |
| September 30, 2020 | -107.34M |
| June 30, 2020 | -88.63M |
| Date | Value |
|---|---|
| March 31, 2020 | -45.76M |
| December 31, 2019 | -34.36M |
| September 30, 2019 | 161.03M |
| June 30, 2019 | 151.66M |
| March 31, 2019 | 129.75M |
| December 31, 2018 | 133.73M |
| September 30, 2018 | -48.64M |
| June 30, 2018 | -54.57M |
| March 31, 2018 | -51.53M |
| December 31, 2017 | -51.39M |
| September 30, 2017 | -31.86M |
| June 30, 2017 | -35.44M |
| March 31, 2017 | -42.87M |
| December 31, 2016 | -42.03M |
| September 30, 2016 | -68.29M |
| June 30, 2016 | -68.25M |
| March 31, 2016 | -62.65M |
| December 31, 2015 | -64.48M |
| September 30, 2015 | -67.68M |
| June 30, 2015 | -66.21M |
| March 31, 2015 | -63.23M |
| December 31, 2014 | -54.75M |
| September 30, 2014 | -37.13M |
| June 30, 2014 | -31.25M |
| March 31, 2014 | -26.32M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Moderna, Inc. | -1.244B |
| Sarepta Therapeutics, Inc. | 58.34M |
| Revolution Medicines, Inc. | -1.232B |
| Intellia Therapeutics, Inc. | -348.69M |
| Denali Therapeutics, Inc. | -466.26M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -177.47M |
| Cash from Investing (Quarterly) | 43.68M |
| Cash from Financing (Quarterly) | -0.449M |
| Free Cash Flow Per Share (Quarterly) | -1.265 |
| Free Cash Flow to Equity (Quarterly) | -184.24M |
| Free Cash Flow to Firm (Quarterly) | -156.76M |
| Free Cash Flow Yield | -0.85% |